T-cell receptor (TCR) recognition of prostatic acid phosphatase (PAP) peptide–major histocompatibility complex (MHC) (TCR-PAP-MHC)

The T-cell receptor (TCR) recognition of prostatic acid phosphatase (PAP) peptide–major histocompatibility complex (MHC) is a fundamental interaction in prostate cancer immunotherapy. PAP is a 100-kDa glycoprotein primarily produced by the prostate gland and is significantly overexpressed in prostate adenocarcinoma (UniProt P15309). The therapeutic strategy involves presenting PAP-derived peptides on MHC Class I or II molecules to activate the patient's immune system. When a TCR specifically binds to the PAP-MHC complex, it initiates a signaling cascade that leads to the activation and expansion of PAP-specific cytotoxic T-lymphocytes (CTLs) (Fong et al., 2001). These CTLs then circulate and target malignant cells that display the PAP-MHC complex on their surface, inducing apoptosis. This mechanism is most notably utilized by Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (Kantoff et al., 2010). Other investigational therapies, such as DNA vaccines (e.g., pTVG-HP), also target this interaction to stimulate a durable anti-tumor immune response (McNeel et al., 2009). Monitoring the frequency of T-cells that recognize this complex serves as a biomarker for the induction of an active immune response.

Other names

PAP-specific T-cell receptorProstatic acid phosphatase-MHC complexPAP-HLA complexACPP-MHC interaction

Activation of T-cells through the specific recognition of PAP-derived peptides presented on MHC molecules, leading to targeted lysis of prostate cancer cells.